激活诱导的脱氨酶单倍剂量不足对体内外抗体多样化和染色体易位的影响
Haploinsufficiency of activation-induced deaminase for antibody diversification and chromosome translocations both in vitro and in vivo.
作者信息
Sernández Isora V, de Yébenes Virginia G, Dorsett Yair, Ramiro Almudena R
机构信息
DNA Hypermutation and Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
出版信息
PLoS One. 2008;3(12):e3927. doi: 10.1371/journal.pone.0003927. Epub 2008 Dec 12.
The humoral immune response critically relies on the secondary diversification of antibodies. This diversification takes places through somatic remodelling of the antibody genes by two molecular mechanisms, Class Switch Recombination (CSR) and Somatic Hypermutation (SHM). The enzyme Activation Induced Cytidine Deaminase (AID) initiates both SHM and CSR by deaminating cytosine residues on the DNA of immunoglobulin genes. While crucial for immunity, AID-catalysed deamination is also the triggering event for the generation of lymphomagenic chromosome translocations. To address whether restricting the levels of AID expression in vivo contributes to the regulation of its function, we analysed mice harbouring a single copy of the AID gene (AID(+/-)). AID(+/-) mice express roughly 50% of normal AID levels, and display a mild hyperplasia, reminiscent of AID deficient mice and humans. Moreover, we found that AID(+/-) cells have an impaired competence for CSR and SHM, which indicates that AID gene dose is limiting for its physiologic function. We next evaluated the impact of AID reduction in AID(+/-) mice on the generation of chromosome translocations. Our results show that the frequency of AID-promoted c-myc/IgH translocations is reduced in AID(+/-) mice, both in vivo and in vitro. Therefore, AID is haploinsufficient for antibody diversification and chromosome translocations. These findings suggest that limiting the physiologic levels of AID expression can be a regulatory mechanism that ensures an optimal balance between immune proficiency and genome integrity.
体液免疫反应严重依赖于抗体的二次多样化。这种多样化通过两种分子机制对抗体基因进行体细胞重塑来实现,即类别转换重组(CSR)和体细胞高频突变(SHM)。酶激活诱导胞苷脱氨酶(AID)通过使免疫球蛋白基因DNA上的胞嘧啶残基脱氨来启动SHM和CSR。虽然AID对免疫至关重要,但AID催化的脱氨也是淋巴瘤发生性染色体易位产生的触发事件。为了研究在体内限制AID表达水平是否有助于其功能的调节,我们分析了携带单拷贝AID基因的小鼠(AID(+/-))。AID(+/-)小鼠表达的AID水平约为正常水平的50%,并表现出轻度增生,这与AID缺陷的小鼠和人类相似。此外,我们发现AID(+/-)细胞的CSR和SHM能力受损,这表明AID基因剂量对其生理功能具有限制作用。接下来,我们评估了AID(+/-)小鼠中AID减少对染色体易位产生的影响。我们的结果表明,无论是在体内还是体外,AID(+/-)小鼠中AID促进的c-myc/IgH易位频率均降低。因此,AID在抗体多样化和染色体易位方面是单倍剂量不足的。这些发现表明,限制AID表达的生理水平可能是一种调节机制,可确保免疫能力和基因组完整性之间的最佳平衡。